FDA Approves Signos’ First-Ever Glucose Monitoring System for Weight Loss

The FDA has approved Signos’ first-ever glucose monitoring system designed specifically for weight loss, providing Americans a new, accessible option for weight management. Unlike traditional treatments like GLP-1 drugs or bariatric surgery, Signos’ system uses an AI platform paired with a Dexcom continuous glucose monitor to deliver personalized, real-time guidance. Membership plans cost $129–$139 for three to six months. The system can complement existing therapies or help maintain weight loss post-treatment. It tracks glucose, food intake, and exercise, enabling users to understand body responses and adopt sustainable lifestyle changes, aiming to address the U.S. obesity epidemic effectively.